My watch list  

80 Current news of UCB


You can refine your search further. Select from the filter options on the left to narrow down your results.

Evotec and UCB sign multi-year CNS pharmacology agreement


Evotec AG announced a collaboration with UCB to provide a broad range of in vitro pharmacology services. Under the terms of the three-year agreement, Evotec will support UCB's in vitro pharmacology team in drug discovery projects across multiple target classes, particularly in the CNS space. Key ...


Major pharma companies sign up to groundbreaking Parkinson's consortium


Seven of the world's largest pharmaceutical companies have signed up to a groundbreaking consortium aimed at accelerating the development of safe and effective therapies for Parkinson's. The Critical Path for Parkinson's consortium will bring together leading academics; industry members AbbVie, ...


UCB and Baylor College of Medicine launch strategic alliance in neurodegeneration

Strategic collaboration to discover transformational therapies for neurodegenerative disease


UCB and Baylor College of Medicine announced that they have started a strategic research alliance, led at Baylor by Professor Huda Zoghbi, that aims to discover new therapeutics to treat neurodegenerative disease. This research alliance reflects UCB’s strategy to accelerate discovery and ...


UCB announces Phase 3 clinical trial program for epratuzumab in Systemic Lupus Erythematosus did not meet primary endpoint


UCB announced that the two EMBODY™ Phase 3 clinical studies for epratuzumab in Systemic Lupus Erythematosus (SLE) did not meet their primary clinical efficacy endpoints in either dose in both studies. Treatment response in patients who received epratuzumab in addition to standard therapy was not ...


UCB to focus on core business in India

UCB to sell its established brands portfolio in India to Dr. Reddy’s for € 118 million


In line with its strategic focus, UCB announces it has entered an agreement with Dr. Reddy’s to sell its established brands in India, including its franchises in the areas of allergies and respiratory disorders. The amount of the transaction amounts to INR 8000 million (~ €118 million). The ...


UCB secures multimillion pound funding boost from UK Government


UCB announced that its joint bid with five other UK-based organisations has been selected as a recipient of the Government’s 2014 Advanced Manufacturing Supply Chain Initiative (AMSCI), which will result in a £6.2 million grant to support the development of novel biologic treatments.The winning ...


Dermira and UCB announce start of Phase 3 program for CIMZIA® (certolizumab pegol) in psoriasis


Dermira, Inc. and UCB announced that the first patients have been dosed in the Phase 3 clinical program designed to evaluate the efficacy and safety of CIMZIA® (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis. This is an important step forward in the ...


UCB to sell its U.S. specialty generics business Kremers Urban for US$ 1,525 million


UCB, Advent International and Avista Capital Partners, two private equity firms with a strong healthcare focus, announced they have entered into a definitive agreement providing for the acquisition of UCB’s US specialty generics subsidiary, Kremers Urban Pharmaceuticals Inc. ("KU"), by Advent and ...


Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam


UCB announced an important advance in its research and development pipeline with positive topline results from the latest Phase 3 study with brivaracetam. This study was designed to evaluate the efficacy and safety of brivaracetam (100 and 200 mg/day, without titration) compared to placebo, as ...


Evotec achieves first milestones in multi-target deal with UCB


Evotec AG announced that it has achieved first milestones in its multi-year, multi-target integrated drug discovery collaboration with UCB in the field of immunology. The milestones were achieved upon the progression of certain projects into hit-to-lead and into lead optimisation. Dr Mario ...


Page 1 From 8
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE